表紙
市場調查報告書

印度的醫藥品市場未來預測 (2019∼2019年)

Indian Pharmaceutical Market Forecast 2019-2029

出版商 Visiongain Ltd 商品編碼 346223
出版日期 內容資訊 英文 212 Pages
商品交期: 最快1-2個工作天內
價格
印度的醫藥品市場未來預測 (2019∼2019年) Indian Pharmaceutical Market Forecast 2019-2029
出版日期: 2019年05月09日內容資訊: 英文 212 Pages
簡介

印度的醫藥品市場將在2018年達到288億美元的規模,在2019年∼2024年間預測將以16.6%的年複合成長率 (CAGR) 持續成長。尤其是,心血管疾病和感染疾病的治療藥需求今後預計將大幅增加。

本報告提供印度的醫藥品市場相關調查分析,市場基本結構和背景情況,收益趨勢的預測,主要企業的評估,促進因素、阻礙因素,預測等系統性資訊。

第1章 報告概要

第2章 印度的醫療:概要

  • 印度:人口統計指標概要
  • 印度的醫療制度:概要
    • Rashtriya Swasthya Bima Yojana:最底層勞工用醫療保險的提供
  • 印度的醫療費分析

第3章 印度的醫藥品的管理體制

  • 監督機構
    • 醫療、家庭福利省 (MoHFW)
    • 化學產品、肥料省 (MoC&F)
  • 政府的相關機關
  • 印度的醫藥品市場的法規、規定:一覽
  • 市場進入
    • 醫療制度
    • HTA (Health Technology Assessment)的現狀
    • 藥價趨勢
    • 醫藥品的醫療費償付

第4章 印度的醫藥品市場:討論與預測

  • 在世界第3大大市場
  • 市場收益額的預測值 (總額,今後12年份)

第5章 印度國內的醫療需求

  • 各種疾病的患病人數 (今後11年份)
  • 各種疾病的發病數量 (今後11年份)
  • 各種疾病的死亡率 (今後11年份)
    • 印度國內的主要的死因
    • 主要的死因:死亡率的預測 (今後11年份)

第5章 印度的醫藥品市場:主要的治療領域

  • 主要的治療領域:概要
  • 市場預測:主要的各治療領域 (今後11年份)
  • 感染疾病治療藥
    • 市場預測 (今後11年份)
      • 腹瀉
      • 下呼吸道感染疾病
      • 結核
      • 瘧疾
      • HIV
    • 推動及阻礙市場要素
  • 心血管疾病治療藥
  • 腸胃疾病治療藥
  • 呼吸疾病治療藥
  • 疼痛緩和藥/止痛藥
  • 糖尿病治療藥
  • 維他命/礦物質/營養劑
  • 皮膚病治療藥
  • 中樞神經系統 (CNS) 疾病治療藥
  • 婦產科疾病治療藥
  • 其他的疾病的治療藥

第7章 印度的醫藥品市場:主要藥物的種類

  • 印度市場上醫藥品的種類:概要
  • 主要種類的醫藥品的成長率預測 (今後11年份)
  • 學名藥 - 印度佔市場大半部分存在
    • 市場預測 (今後11年份)
    • 推動及阻礙市場要素等
  • 成藥
  • 專利醫藥品
  • 生物相似藥醫藥品

第8章 印度的醫藥品市場代表性企業

  • 印度的醫藥品市場:概要
    • 對於印度的醫藥品相關的專利法,和大型製藥企業的影響力
  • 印度國內的製藥企業前50大企業
  • Sun Pharmaceuticals Industries Limited
    • 業績趨勢 (過去10年份)
    • 企業發展/資本交易趨勢
  • Abbott Healthcare Private Limited (Abbott India)
  • Cipla Ltd.
  • Cadila Healthcare Limited
  • GlaxoSmithKline Pharmaceuticals Limited
  • Pfizer Limited., India
  • Lupin
  • Sanofi India Limited
  • Intas Pharmaceuticals Limited
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Limited

第9章 印度的醫藥品市場定性分析

  • 印度的醫藥品市場:促進、阻礙因素
  • 印度的醫藥品市場SWOT分析
  • 優勢
    • 醫療制度的投資擴大
    • 疾病負擔、GDP的增加
    • 印度的總人口:2030年成為世界最大
    • 作為製藥產業的外包處有前途的印度
  • 弱點
    • 來自嚴格的價格法規對市場的不良影響
    • 由於貧乏的醫療基礎設施,潛在的市場縮小
    • 競爭激烈伴隨的藥價降低
  • 機會
    • 世界規模的學名藥需求增加
    • 國家農村健康任務 (NRHM):農村的醫療獲取的改善
    • 由跨國公司 (MNC) 的巨額投資預測
    • 作為良機躍進創新的生物科技部門:專利到期
  • 威脅
    • 學名藥:其他低成本出口國的崛起
    • 印度政府今後也將維持醫療費的增額趨勢嗎?
    • 來自當局近幾年的警告和禁止出口令:製藥企業的自信喪失
  • 波特的五力分析
    • 企業間競爭 (高)
    • 新加入企業的威脅 (低)
    • 供應商談判力 (中)
    • 買主談判力 (高)
    • 替代產品的威脅 (低)

第10章 結論

  • 印度的醫藥品市場:全球市場的佔有率的擴大
  • 慢性疾病患者的劇增
  • 推動市場要素
  • 阻礙市場要素
  • 分析結果

第11章 用語一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0419

The Indian pharmaceuticals market is estimated to have reach $28.8bn in 2018 and is expected to grow at a CAGR of 16.6% in the first half of the forecast period. The market for cardiovascular medication is the fastest growing segment of the Indian pharmaceutical market, followed by the anti-infective segment.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 212-page report you will receive 121 charts - all unavailable elsewhere.

The 212-page report provides clear detailed insight into the Indian Pharmaceutical Market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Indian Pharmaceuticals Market forecasts from 2019-2029

Revenue forecasts for the leading therapeutic areas in India from 2019-2029:

  • Anti-Infectives Therapeutics
  • Cardiovascular Therapeutics
  • Dermatological Therapeutics
  • Diabetes Therapeutics
  • Gastrointestinal Therapeutics
  • Gynaecology Therapeutics
  • CNS Therapeutics
  • Pain Relief/Analgesics Therapeutics
  • Respiratory Therapeutics
  • Vitamins/Minerals/Nutrients Therapeutics
  • Other Therapeutics

This report also discusses factors that drive and restrain these submarkets.

Revenue forecasts for the leading drug types in India from 2019-2029:

  • Generic Drugs
  • Over-the-Counter (OTC) Drugs
  • Patented Drugs
  • Biosimilar Drugs

This report also discusses factors that drive and restrain these submarkets.

Profiles and discusses the leading companies in the Indian pharmaceutical market:

  • Abbott Healthcare Private Limited (Abbott India)
  • Cadila Healthcare Limited
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline Pharmaceuticals Limited
  • Glenmark Pharmaceuticals Limited
  • Intas Pharmaceuticals Limited
  • Lupin
  • Pfizer Limited
  • Sanofi India Limited
  • Sun Pharmaceuticals Industries Limited

(Revenues are provided for those companies whose financial information is available on the public domain)

  • Analysis of the drivers and restraints of the Indian Pharmaceutical market
  • The report also discusses the Porter's Five Forces Analysis and SWOT Analysis of the Indian Pharmaceuticals Market

This report also discusses:

  • Indian healthcare system and Indian healthcare expenditure
  • Indian pharmaceutical regulatory framework, laws & regulations, market access, regulatory bodies
  • Disease prevalence and incidence in India, disease mortality rates in India, top causes of death in India, mortality projections from 2019-2029

What this report provides:

  • The Indian pharmaceutical market forecasts and analysis from 2019 to 2029
  • Analysis and forecasts for the Indian pharmaceutical submarkets from 2019 to 2029
  • Profiles of the leading companies operating within the Indian pharmaceutical industry
  • SWOT analysis and Porter's five forces analysis of the major strengths and weaknesses of the Indian pharmaceutical market together with the opportunities available and the key threats faced

Visiongain's study is intended for anyone requiring commercial analyses for the Indian Pharmaceuticals Market. You find data, trends and predictions.

Buy our report today Indian Pharmaceutical Market Forecast 2019-2029: Infectious Disease, Cardiovascular, Gastrointestinal, Respiratory, Pain Relief / Analgesics, Diabetes, Vitamins/ Minerals/ Nutrients, Dermatology, CNS, Gynaecology, Generic, OTC, Patented, Biosimilar, Leading Companies’.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 The Indian Pharmaceutical Market Overview
  • 1.2 Indian Pharmaceutical Market Segmentation
  • 1.3 Why You Should Read This Report
  • 1.4 How This Report Delivers
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report For?
  • 1.7 Methodology
  • 1.8 Frequently Asked Questions (FAQ)
  • 1.9 Associated Reports
  • 1.10 About Visiongain

2. Indian Healthcare: Overview

  • 2.1 India: Demographic Indicators Overview
  • 2.2 Indian Healthcare System: Overview
    • 2.2.1 Rashtriya Swasthya Bima Yojana - Bringing Healthcare Coverage to India's Poorest Workers
  • 2.3 Analysis of India's Healthcare Expenditure

3. Indian Pharmaceutical Regulatory Framework

  • 3.1 National Regulatory Bodies
    • 3.1.1 Ministry of Health & Family Welfare (MoHFW)
    • 3.1.2 Ministry of Chemicals and Fertilizers (MoC&F)
  • 3.2 State Regulatory Bodies (State Food and Drug Administrations (FDAs)
  • 3.3 Laws & Regulations for Indian Pharmaceutical Market
    • 3.3.1 The Drugs and Cosmetics Act, 1940
    • 3.3.2 The Pharmacy Act, 1948
    • 3.3.3 The Drugs & Magic Remedies Act, 1954
    • 3.3.4 The Narcotic Drugs and Psychotropic Substances Act, (NDPS)1985
    • 3.3.5 The Medicinal and Toilet Preparations Act, 1956
    • 3.3.6 The Drugs Price Control Order (DPCO), 1995
    • 3.3.7 Indian Patent Act 1970
    • 3.3.8 The Drugs Price Control Order (DPCO), 2013
    • 3.3.9 Good Clinical Practices (GCP)
    • 3.3.10 Good Laboratory Practices (GLP)
  • 3.4 Market Access
    • 3.4.1 Healthcare System
    • 3.4.2 Status of Health Technology Assessment (HTA)
    • 3.4.3 Pricing
    • 3.4.4 Reimbursement of Drugs

4. Indian Pharmaceutical Market: Discussions and Predictions 2019-2029

  • 4.1 Indian Pharmaceutical Market: The Third Biggest Market in the World by Volume
  • 4.2 Indian Pharmaceuticals Market: Overall Revenue Forecast 2018-2029

5. Medical Treatment Needs in India, 2019-2029

  • 5.1 Disease Prevalence in India, 2019-2029
  • 5.2 Disease Incidence in India, 2019-2029
  • 5.3 Disease Mortality Rates in India, 2019-2029
    • 5.3.1 Top Causes of Death in India
    • 5.3.2 Top Causes of Death in India: Mortality Projections, 2019-2029

6. Indian Pharmaceutical Market: Leading Therapeutic Areas, 2019-2029

  • 6.1 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Overview, 2018
  • 6.2 Indian Pharmaceutical Market: Leading Therapeutic Areas Forecasts, 2019-2029
  • 6.3 Infectious Disease Drugs: Overview, 2018
    • 6.3.1 Infectious Disease Drugs Market: Forecast, 2019-2029
    • 6.3.2 Diarrheal Diseases Responsible for Over Half a Million Annual Deaths, 2018
    • 6.3.3 Lower Respiratory Tract Infections Among Leading Causes of Death
    • 6.3.4 Tuberculosis Still Rife in India
    • 6.3.5 Malaria, Risk and Opportunity
    • 6.3.6 HIV in India: Growing Therapeutic Area Worth Watching
    • 6.3.7 Drivers and Restraints for the Infectious Diseases Pharmaceutical Segment
  • 6.4 Cardiovascular Therapeutics Segment: Overview, 2018
    • 6.4.1 Cardiovascular Disease - India's Leading Cause of Death, 2018
    • 6.4.2 Cardiovascular Drugs Market: Forecast, 2019-2029
  • 6.5 Gastro-Intestinal Therapeutic Segment: Overview, 2018
    • 6.5.1 Gastro-Intestinal Drugs Market: Forecast, 2019-2029
    • 6.5.2 Gastro-Intestinal Therapeutics in India: Challenges and Opportunities
    • 6.5.3 Drivers and Restraints for the Gastro-Intestinal Therapeutics Segment
  • 6.6 Respiratory Therapeutic Segment: Overview, 2018
    • 6.6.1 Respiratory Disease Drugs Market: Forecast, 2019-2029
    • 6.6.2 Drivers and Restraints for the Respiratory Therapeutics Segment
  • 6.7 Pain Relief / Analgesics Therapeutic Segment: Overview, 2018
    • 6.7.1 Pain Relief / Analgesics Drugs Market: Forecast, 2019-2029
    • 6.7.2 Drivers and Restraints for the Pain Relief/Analgesics Therapeutics Segment
  • 6.8 Diabetes Therapeutic Segment: Overview, 2018
    • 6.8.1 Diabetes Therapeutics Market: Forecast, 2019-2029
    • 6.8.2 Drivers and Restraints for the Diabetes Therapeutics Segment
  • 6.9 Vitamins / Minerals / Nutrients Therapeutic Segment: Overview, 2018
    • 6.9.1 Vitamins / Minerals / Nutrients Therapeutics Market: Forecast, 2019-2029
    • 6.9.2 Vitamins / Minerals / Nutrients in India: Challenges and Opportunities
    • 6.9.3 Drivers and Restraints for the Vitamins / Minerals / Nutrients Therapeutics Segment
  • 6.10 Dermatological Therapeutic Segment: Overview, 2018
    • 6.10.1 Dermatological Therapeutics Market: Forecast, 2019-2029
    • 6.10.2 Drivers and Restraints for the Dermatological Therapeutics Segment
  • 6.11 Central Nervous System (CNS) Therapeutics: Overview, 2018
    • 6.11.1 CNS Drugs Market: Forecast, 2019-2029
    • 6.11.2 Intentional Injury Among the Top 10 Leading Causes of Death, 2018
    • 6.11.3 India's Aging Population: Driver for the CNS Segment
    • 6.11.4 Drivers and Restraints for the CNS Therapeutics Segment
  • 6.12 Gynaecological Treatment Market Overview: 2018
    • 6.12.1 Infant Mortality Still High in India
    • 6.12.2 Indian Gynaecological Treatments Market: Forecast, 2019-2029
    • 6.12.3 Drivers and Restraints for the Gynaecological Segment
  • 6.13 Other Pharmaceutical Products Market Overview: 2018
    • 6.13.1 Incidence of Cancer is Rising in India
    • 6.13.2 Indian Other Treatments Market: Forecast, 2019-2029

7. Indian Pharmaceutical Market: Leading Drug Types, 2019-2029

  • 7.1 Drug Types in the Indian Market: Overview, 2018
  • 7.2 Growth Forecasts for Leading Drug Types in India, 2019-2029
  • 7.3 Generic Drugs Dominate the Indian Pharmaceutical Market
    • 7.3.1 Indian Generics: Overview, 2018
    • 7.3.2 Indian Generic Drugs Market: Forecast, 2018-2029
    • 7.3.3 Branded Generics Preferred by Many Indian Patients
    • 7.3.4 Drivers and Restraints for the Generic Drug Market in India
  • 7.4 Indian Over-The-Counter (OTC) Drugs Market: Overview, 2018
    • 7.4.1 Indian OTC Market: Forecast, 2019-2029
    • 7.4.2 Drivers and Restraints of the Indian OTC Market
  • 7.5 Indian Patented Drugs Market: Overview, 2018
    • 7.5.1 Indian Patented Drugs Market: Forecasts, 2019-2029
    • 7.5.2 Drivers and Restraints for the Indian Patented Drugs Market
  • 7.6 Indian Biosimilar Drugs, 2018
    • 7.6.1 Indian Biosimilar Drugs Market: Forecast, 2019-2029
    • 7.6.2 A Number of Blockbuster Drugs Coming Off-Patent Over the Next Decade
    • 7.6.3 Drivers and Restraints of the Indian Biosimilar Drugs Market

8. The Leading Companies in the Indian Pharmaceuticals Market

  • 8.1 Indian Pharmaceuticals Market Overview
    • 8.1.1 Indian Pharmaceutical Patent Law and the Effect on Big Pharmaceutical Companies
  • 8.2 Top 50 Domestic Indian Pharmaceutical Companies, 2018
  • 8.3 Sun Pharmaceuticals Industries Limited
    • 8.3.1 Sun Pharma: Global Presence
      • 8.3.1.1 Sun Pharmaceutical Sales by Region, 2017
    • 8.3.2 Sun Pharmaceuticals Business Performance 2008-2017
    • 8.3.3 Sun Pharmaceutical: The Acquisition of Ranbaxy Laboratories is the Largest Ever Deal Made by an Indian Pharmaceutical Company
      • 8.3.3.1 Other Major M&A Activity
  • 8.4 Abbott Healthcare Private Limited (Abbott India)
    • 8.4.1 Abbott India: Business Performance 2007-2017
    • 8.4.2 Abbott India: Major and Recent M&A Activity
  • 8.5 Cipla Ltd.
    • 8.5.1 Cipla: Business Performance 2008-2017
    • 8.5.2 Cipla Ltd.: Major and Recent Activity
  • 8.6 Cadila Healthcare Limited
    • 8.6.1 Cadila: Business Performance 2008-2017
    • 8.6.2 Cadila Healthcare Revenue by Therapeutic Area 2017
  • 8.7 GlaxoSmithKline Pharmaceuticals Limited
    • 8.7.1 GlaxoSmithKline India: Business Performance 2008-2017
  • 8.8 Pfizer Limited., India
    • 8.8.1 Pfizer India: Business Performance 2008-2017
  • 8.9 Lupin
    • 8.9.1 Lupin: Business Performance 2008-2017
    • 8.9.2 Lupin Revenue by Therapeutic Area, 2017
  • 8.10 Sanofi India Limited
    • 8.10.1 Sanofi India Limited: Business Performance 2008-2017
    • 8.10.2 Sanofi India Limited Revenue by Business Segments, 2017
    • 8.10.3 Sanofi India Limited Revenue by Geographical Area, 2017
    • 8.10.4 Sanofi India Limited Recent Activities
  • 8.11 Intas Pharmaceuticals Limited
    • 8.11.1 Intas Pharmaceuticals Limited: Business Performance 2008-2017
  • 8.12 Dr. Reddy's Laboratories Ltd.
    • 8.12.1 Dr. Reddy's Laboratories Ltd: Business Performance 2008-2017
    • 8.12.2 Dr. Reddy's Laboratories Ltd. Revenue by Business Segments, 2017
    • 8.12.3 Dr. Reddy's Laboratories Ltd Global Generics Segment Revenue by Geographical Area, 2017
  • 8.13 Glenmark Pharmaceuticals Limited
    • 8.13.1 Glenmark Pharmaceuticals Limited: Business Performance 2008-2017
    • 8.13.2 Glenmark Pharmaceuticals Limited Revenue by Geographical Area, 2017
    • 8.13.3 Glenmark Pharmaceuticals Limited Recent Activities

9. Qualitative Analysis of the Indian Pharmaceuticals Market, 2018

  • 9.1 Indian Pharmaceutical Market: Drivers and Restraints
  • 9.2 SWOT Analysis of the Indian Pharmaceuticals Market
  • 9.3 Strengths
    • 9.3.1 Increasing Investment in the Healthcare System
    • 9.3.2 The Disease Burden and GDP Growing
    • 9.3.3 India's Population Set to Become the World's Largest by 2030
    • 9.3.4 India Popular for Pharmaceutical Outsourcing
  • 9.4 Weaknesses
    • 9.4.1 Stringent Pricing Regulations Hit the Indian Pharmaceuticals Market
    • 9.4.2 Poor Infrastructure Threatens to Hinder Market Potential
    • 9.4.3 Intense Competition Driving Down Drug Prices
  • 9.5 Opportunities
    • 9.5.1 Global Demand for Generics Rising
    • 9.5.2 National Rural Health Mission Driving Healthcare Access in Rural Areas
    • 9.5.3 Significant Investment from MNCs Expected
    • 9.5.4 Innovative Biotechnology Sector Set to Capitalise on Patent Expiries
  • 9.6 Threats
    • 9.6.1 Rise of Other Low-Cost Generic Exporters
    • 9.6.2 Will the Indian Government Stick to Increasing Healthcare Expenditure?
    • 9.6.3 Recent Warnings and Export Bans from Regulatory Bodies Hit Confidence in Indian Pharmaceuticals
  • 9.7 Porter's Five Forces Analysis of the Indian Pharmaceuticals Market
    • 9.7.1 Rivalry Among Competitors [High]
    • 9.7.2 Threat of New Entrants [Low]
    • 9.7.3 Power of Suppliers [Medium]
    • 9.7.4 Power of Buyers [High]
    • 9.7.5 Threat of Substitutes [Low]

10. Conclusion

  • 10.1 The Indian Pharmaceuticals Market: Growing Global Market Share
  • 10.2 Indian Pharmaceutical Market: Chronic Diseases Becoming Increasingly Prevalent
  • 10.3 Commercial Drivers of the Indian Pharmaceuticals Market
  • 10.4 Commercial Restraints of the Indian Pharmaceuticals Market
  • 10.5 Concluding Remarks

11. Glossary

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form

List of Tables

  • Table 4.1 The Indian Pharmaceutical Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 5.1 Leading Causes of Death in India, Proportion of Total Deaths (%) 2014
  • Table 5.2 Leading Types of Cancer in India by Age-Standardised Death Rate (per 100,000 People), 2014
  • Table 5.3 Causes of Death in India by World Ranking, 2014
  • Table 6.1 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Market Share (%), 2018, 2024, 2029
  • Table 6.2 The Indian Pharmaceutical Market: Revenue ($bn), AGR (%) and CAGR (%) by Therapeutic Area, 2018-2029
  • Table 6.3 The Infectious Disease Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.4 The Indian Cardiovascular Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.5 Indian Gastro-Intestinal Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.6 The Indian Respiratory Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.7 Indian Pain Relief/Analgesics Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.8 Indian Diabetes Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.9 Indian Vitamins / Minerals / Nutrients Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.10 Indian Dermatological Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.11 Indian CNS Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.12 Indian Gynaecological Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.13 Indian Other Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 7.1 Leading Drug Types in the Indian Pharmaceutical Market: Revenue ($bn) and Market Share (%), 2019, 2024 and 2029
  • Table 7.2 Indian Pharmaceutical Market: Revenue ($bn), AGR (%), CAGR (%) by Drug Type, 2019-2029
  • Table 7.3 Indian Generic Drugs Market: Revenue ($bn), AGR (%) and CAGR (%) 2018-2029
  • Table 7.4 Indian OTC Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 7.5 Indian Patented Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 7.6 Selected Biosimilar Therapeutics on the Indian Market, 2018
  • Table 7.7 Indian Biosimilar Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 7.8 Selected Blockbuster Biologic Patent Expiries in the US and EU, 2015-2028
  • Table 7.9 Selected Late-Stage Biosimilar Pipeline Products, 2015
  • Table 8.1 Top 50 Companies in the Indian Pharmaceutical Market: Revenue (Rs. m), Revenue ($m) and Market Share (%), 2017
  • Table 8.2 Sun Pharmaceuticals: Revenue (Rs. m), Revenue ($m) and Revenue Share (%) by Business Area, FY 2017
  • Table 8.3 Sun Pharmaceuticals: Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.4 Sun Pharmaceuticals: M&A Activity, 1997-2016
  • Table 8.5 Abbott India: Market Share (%) and Market Rank of Key Brands
  • Table 8.6 Abbott India: Revenue (Rs. m), AGR (%) and CAGR (%), 2006-2017
  • Table 8.7 Cipla: Total Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.8 Cipla: Revenue (Rs. m), Revenue ($m) and Revenue Share (%) by Geographical Area, 2017
  • Table 8.9 Cadila Healthcare Ltd.: Total Revenue (Rs. m), Total Revenue ($m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.10 Cadila Healthcare Ltd.: Revenue (Rs.m) and Revenue Share (%) by Therapeutic Area, 2017
  • Table 8.11 GlaxoSmithKline India: Key Products in the Indian Market, 2017
  • Table 8.12 GlaxoSmithKline India Total Revenue (Rs. m), AGR (%) and CAGR (%), 2007-2017
  • Table 8.13 Pfizer India: Leading Brands on the Indian Market 2017
  • Table 8.14 Pfizer India: Total Revenue (Rs.m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.15 Lupin: Total Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.16 Lupin: Revenue Share (%) by Therapeutic Area, 2017
  • Table 8.17 Sanofi India Limited: Major Products,2017
  • Table 8.18 Sanofi India Limited: Total Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.19 Sanofi India Limited: Revenue (Rs. m) and Revenue Share (%) by Domestic Segment, 2017
  • Table 8.20 Sanofi India Limited: Revenue (Rs. m) and Revenue Share (%) by Branded drugs, 2017
  • Table 8.21 Sanofi India Limited: Revenue (Rs. m), and Revenue Share (%) by Geographical Area, 2017
  • Table 8.22 Intas Pharmaceuticals Limited: Total Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.23 Dr. Reddy's Laboratories Ltd: Major Products,2017
  • Table 8.24 Dr. Reddy's Laboratories Ltd: Total Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.25 Dr. Reddy's Laboratories Ltd: Revenue (Rs. m), and Revenue Share (%) by Business Segment, 2017
  • Table 8.26 Dr. Reddy's Laboratories Ltd: Revenue (Rs.m), and Revenue Share (%) by Geographical Area, 2017
  • Table 8.27 Glenmark Pharmaceuticals Limited: Total Revenue (Rs.m), AGR (%) and CAGR (%), 2008-2017
  • Table 9.1 SWOT Analysis of the Indian Pharmaceuticals Market

List of Figures

  • Figure 1.1 Indian Pharmaceutical Market: Overview of Submarkets
  • Figure 2.1 Indian Population: Rural and Urban (Mn),1960-2020
  • Figure 2.2 Indian Population: Total (Mn) and Annual Population Growth Rate (%), 1960-2020
  • Figure 2.3 Indian GDP ($bn) and Growth Rate (%), 2010-2020
  • Figure 2.4 Access to Improved Water Sources as a Proportion of Total Population (%) and Access to Improved Sanitation as a Proportion of Total Population (%), 2008-2020
  • Figure 2.5 Indian GDP ($bn) and Health Expenditure as a Proportion of GDP (%), 2006-2014
  • Figure 2.6 Health Expenditure: Public Health expenditure as a Proportion of Total Health Expenditure (%) and Out of Pocket Expenditure as a Proportion of Private Health Expenditure 2008-2014
  • Figure 3.1 National Regulatory Bodies Regulating the Indian Pharmaceutical Market
  • Figure 4.1 The Indian Pharmaceutical Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 5.1 Leading Causes of Death in India, Proportion of Total Deaths (%) 2014
  • Figure 6.1 Leading Therapeutic Areas in the Indian Pharmaceuticals Market: Market Share (%), 2018
  • Figure 6.2 Leading Therapeutic Areas in the Indian Pharmaceuticals Market: Market Share (%), 2024
  • Figure 6.3 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Market Share (%), 2029
  • Figure 6.4 The Infectious Disease Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.5 Malaria cases (m), P. falciparum cases (m) and Proportion of P. falciparum cases (%) in India, 1995-2014
  • Figure 6.6 Infectious Diseases Therapeutics Market in India: Drivers and Restraints, 2018-2029
  • Figure 6.7 The Indian Cardiovascular Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.8 Cardiovascular Diseases Therapeutics Market in India: Drivers and Restraints
  • Figure 6.9 Indian Gastro-Intestinal Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.10 Gastro-intestinal Therapeutics Market in India: Drivers and Restraints
  • Figure 6.11 Indian Respiratory Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.12 Respiratory Therapeutics Market in India: Drivers and Restraints, 2018-2029
  • Figure 6.13 Indian Pain Relief/Analgesics Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.14 Pain Relief/Analgesics Therapeutics Market in India: Drivers and Restraints, 2018-2029
  • Figure 6.15 Indian Diabetes Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.16 Diabetes Therapeutics Market in India: Drivers and Restraints
  • Figure 6.17 Indian Vitamins / Minerals / Nutrients Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.18 Vitamins / Minerals / Nutrients Therapeutics Market in India: Drivers and Restraints
  • Figure 6.19 Indian Dermatological Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.20 Dermatological Therapeutics Market in India: Drivers and Restraints
  • Figure 6.21 Indian CNS Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.22 CNS Therapeutics Market in India: Drivers and Restraints
  • Figure 6.23 Indian Gynaecological Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.24 Gynaecological Therapeutics Market in India: Drivers and Restraints
  • Figure 6.25 Indian Other Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 7.1 Leading Drug Types in the Indian Pharmaceutical Market: Market Share (%), 2019
  • Figure 7.2 Leading Drug Types in the Indian Pharmaceutical Market: Market Share (%), 2024
  • Figure 7.3 Leading Drug Types in the Indian Pharmaceutical Market: Market Share (%), 2029
  • Figure 7.4 Indian Generic Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 7.5 Generic Drugs Market in India: Drivers and Restraints
  • Figure 7.6 Indian OTC Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 7.7 OTC Drugs Market in India: Drivers and Restraints
  • Figure 7.8 Indian Patented Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 7.9 Patented Drugs Market in India: Drivers and Restraints
  • Figure 7.10 Indian Biosimilar Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 7.11 Biosimilar Drug Market in India: Drivers and Restraints
  • Figure 8.1 Sun Pharmaceuticals: Revenue Share (%) by Business Area, FY 2017
  • Figure 8.2 Sun Pharmaceuticals: Revenue ($m) and AGR (%), 2008-2017
  • Figure 8.3 Abbott India: Revenue (Rs. m) and AGR (%), 2006-2017
  • Figure 8.4 Cipla Revenue (Rs.m) and AGR (%), 2008-2017
  • Figure 8.5 Cadila Healthcare Ltd.: Revenue Share (%), by Business Area, 2017
  • Figure 8.6 GlaxoSmithKline India: Revenue ($m) and AGR (%), 2007-2017
  • Figure 8.7 Pfizer India: Revenue (Rs.m) and AGR (%), 2007-2016
  • Figure 8.8 Lupin: Revenue (Rs.m) and AGR (%), 2008-2017
  • Figure 8.9 Lupin: Revenue Share (%) by Therapeutic Area, 2017
  • Figure 8.10 Sanofi India Limited: Revenue ($m) and AGR (%), 2008-2017
  • Figure 8.11 Sanofi India Limited: Revenue Distribution by Business Segments, 2017
  • Figure 8.12 Sanofi India Limited: Revenue Distribution by Domestic Segments, 2017
  • Figure 8.13 Sanofi India Limited: Revenue Distribution by Geographical Area, 2017
  • Figure 8.14 Intas Pharmaceuticals Limited: Revenue ($m) and AGR (%), 2008-2017
  • Figure 8.15 Dr. Reddy's Laboratories Ltd: Revenue ($m) and AGR (%), 2008-2017
  • Figure 8.16 Dr. Reddy's Laboratories Ltd: Revenue Distribution by Business Segments, 2017
  • Figure 8.17 Dr. Reddy's Laboratories Ltd: Global Generics Segment Revenue Distribution by Geographical Area, 2017
  • Figure 8.18 Glenmark Pharmaceuticals Limited: Revenue ($m) and AGR (%), 2007-2017
  • Figure 8.19 Glenmark Pharmaceuticals Limited: Revenue Distribution by Geographical Area, 2017
  • Figure 9.1 Indian Pharmaceuticals Market: Drivers and Restraints
  • Figure 9.2 Porter's Five Forces Analysis of the Indian Pharmaceuticals Market

COMPANIES LISTED:

  • Abbott India
  • Able Labs
  • Ajanta Pharma Ltd
  • Akumentis Healthcare Ltd
  • Albert David Ltd
  • Alembic
  • Alkem
  • Almirall
  • Amgen
  • Apex Laboratories Pvt. Ltd
  • Aristo Pharma
  • Ascendis Pharma
  • AstraZeneca
  • Aventis Pharma Limited
  • Bayer
  • Bharat Serums
  • Biocon Ltd
  • Biosintez
  • Blue Cross Laboratories Ltd.
  • Cadila Healthcare Ltd.
  • Caraco
  • Chattem Chemicals, Inc.
  • Cipla
  • Claris Lifesciences
  • Daiichi Sankyo
  • Divis Laboratories
  • Dr. Reddy's Laboratories
  • DUSA Pharma, Inc.
  • Eli Lilly and Company (India) Pvt. Ltd.
  • Emcare
  • Eris Lifesciences
  • Exelan
  • FDC
  • Fourrts (India) Laboratories Pvt, Ltd
  • Franco India
  • GlaxoSmithKline India
  • Glenmark Pharma
  • GSK India
  • Heinz India
  • Helsinn Group
  • Hetero Drugs Ltd
  • Hoechst India Limited
  • Hoechst Marion Roussel Limited
  • Hoechst Pharmaceuticals Private Limited
  • Indoco
  • Indi Pharma Pvt. Ltd.
  • InSite Vision
  • Intas Pharma
  • InvaGen
  • Ipca Laboratories
  • Janssen
  • JB Chemicals
  • JSC Biosintez
  • Lonza
  • Lupin
  • Macleods
  • MannKind Corporation
  • Medley Pharmaceuticals Ltd
  • MedproPhamaceutica (Pty) Ltd
  • Megafine Pharma
  • Merck KGaA
  • Meyer Organics
  • Micro Labs
  • MSD Pharma
  • Natco
  • Novartis India
  • Novo Nordisk
  • Odomzo
  • Pfizer India
  • Pharmalucence
  • Piramal Healthcare
  • Pola Pharma, Inc.
  • Ranbaxy
  • Raptakos, Brett & Co. Ltd
  • Roche Pharma India
  • Sandoz, Novartis Division
  • Sanofi India
  • Seciera
  • Sun Pharmaceuticals
  • Taro Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals (Pty)Ltd
  • The Himalaya Drug Company
  • Torrent Pharma
  • True North
  • Unichem
  • URL's
  • USV
  • Wallace Pharmaceuticals
  • Win-Medicare
  • Wockhardt
  • Wockhardt
  • Zydus Wellness Ltd

List of Organizations Mentioned in the Report:

  • Australia's TGA (Therapeutic Goods Administration)
  • Central Drugs Standard Control Organisation
  • Competition Commission of India (CCI)
  • Dr. M.G.R. Medical University (TNMGRMU)
  • Drug Consultative Committee
  • Drug Controller General of India
  • Medical Council of India
  • MHLW (Ministry of Health, Labour and Welfare)
  • MHRA (Medicines & Healthcare Products Regulatory Agency)
  • Ministry of Chemicals & Fertilisers
  • Ministry of Health and Family Welfare
  • National AIDS Control Organisation (NACO)
  • National Pharmaceutical Pricing Authority
  • Organisation for Economic Co-operation and Development (OECD)
  • State Food and Drug Administrations
  • The Joint United Nations Programme on HIV/AIDS (UNAIDS)
  • US Federal Trade Commission (FTC)
  • World Health Organization (WHO)